Skip to main content
Skip to content
Case File
d-25976House Oversight

Celgene exec Chris Hugin linked to $280 M settlement and political attacks over Revlimid price hikes

Financial Record

The passage identifies a former Celgene executive (Chris Hugin) who was involved in aggressive marketing of Revlimid/Thalomid, a $280 M whistle‑blower settlement, and political targeting by a super‑PA Chris Hugin was a top executive at Celgene during the Revlimid/Thalomid controversy. Celgene paid $280 M to settle a whistle‑blower lawsuit alleging off‑label promotion. A super‑PAC funded by a Revli

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #028416
Pages
2
Persons
5
Integrity
No Hash Available
Loading document viewer...

Ask AI About This Document

0Share
PostReddit
Review This Document

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.